Literature Reviews
doi: 10.25005/2074-0581-2019-21-2-321-327
COGNITIVE IMPAIRMENTS IN PATIENTS WITH ARTERIAL HYPERTENSION

N.Kh. Khamidov, N.M. Khursanov, A.N. Lolaev

Department of Internal Medicine № 2, Avicenna Tajik State Medical University, Dushanbe, Republic of Tajikistan

The presented review of the literature examines the main issues of cognitive function in patients with high blood pressure. More than a quarter of older people have cognitive impairments, and hypertension is seen as a contributing factor to such disorders. An analysis of the effects of some hypotensive drugs on the cognitive functions of patients in this category is given. The findings suggest that effective hypotensive therapy reduces the incidence of cognitive impairment in given patient’s categories.

Keywords: Arterial hypertension, cognitive function , old age, hypotensive therapy.

Download file:

References
  1. Bokaryov IN, Dulin PA, Ovchinnikov UB. Arterial’naya gipertoniya: sovremennoe sostoyanie problemy [Arterial hypertension: modern state of the problem]. Klinicheskaya meditsina. 2017;7:581-6.
  2. Orlova YaA, Plisyuk AG. Novye vozmozhnosti kombinirovannoy terapii arterial’noy gipertonii [New opportunities of combined therapy of arterial hypertension]. Kardiologiya. 2017;6:59-63.
  3. Ostroumova OD, Borisova EB, Pavleeva EC. Variabelnost’ arterial’nogo davleniya [Variability of arterial blood pressure]. Kardiologiya. 2017;11:68- 76.
  4. Word Health Statistics 2014.World Health Organization. 2014
  5. Umarov AA, Khamidov NKh, Umarova SA. Izolirovannaya sistolicheskaya arterial’naya gipertoniya: nekotorye aspekty patogeneza i faktorov riska [Isolated systolic arterial hypertension: some aspects of the pathogenesis and risk factors]. Vestnik Avitsenny [Avicenna Bulletin]. 2011;2:130-4
  6. Yakovlev UM, Khayt GYa. Osnovy geriatricheskoy kardiologii: rukovodstvo dlya prakticheskikh vrachey [Basics of geriatric cardiology: handbook for practitioners]. Moscow, RF: Izdatel’skiy dom Vidar-M; 2011. 424 p.
  7. Vorobyov AA. (red.) Geriatriya v lektsiyakh [Lections on geriatry]. Moscow, RF: N’yudiamed; 2002. 440 p.
  8. Moiseev VS, Kobalava ZhD, Moiseev SV. Vnutrennie bolezni s osnovami dokazatel’noy meditsiny i klinicheskoy farmakologii [Internal medicine with the basics of evidence based medicine and clinical farmacology]. Moscow, RF: GEOTAR-Media; 2010. 828 p
  9. Shabalin VN. (red.) Rukovodstvo po gerontologii [Handbook on gerontology]. Moscow, RF: Tsitadel’-treyd; 2005. 800 p.
  10. Gromova DO, Vakhnina NB. Kognitivnye narusheniya u bol’nykh molodogo i srednego vozrasta: diagnostika i podkhody k terapii [Cognitive impairments in young and middle-aged patients: diagnosis and approaches to therapy]. Nevrologiya. 2017;3:31-40.
  11. Petersen RC, Knopman DS, Boeve BF. Mild cognitive impairment: 10 years later. Arch Neurol. 2009;12:1447-55.
  12. Zakharov VV. Vserossiyskaya programma issledovaniy epidemiologii i terapii kognitivnykh rasstroystv v pozhilom vozraste (“Prometey”) [All-Russian program of investigation of cognitive impairment in old age (“Prometey”)]. Nevrologicheskiy zhurnal. 2006;11:27-32.
  13. Yakhno NN, Preobrazhenskaya IS, Zakharov VV. Rasprostranyonnost’ kognitivnykh narusheniy pri nevrologicheskikh zabolevaniyakh [Prevalence of cognitive impairments for neurological diseases]. Nevrologiya, neyropsikhiatriya, psikhosomatika. 2012;2:30-4.
  14. Zakharov VV, Yakhno NN. Syndrom umerennykh kognitivnykh rasstroystv v pozhilom vozraste: diagnostika i lechenie [Mild cognitive impairment syndrome in old age: diagnosis and treatment]. Russkiy meditsinskiy zhurnal. 2004;10:573-6.
  15. Busse AG, Bischkopf SG. Mild cognitive impairment: prevalence and incidence according to different diagnostic criteria. Results of the Leipzig Longitudinal Study of the Aged. Br J Psych. 2003;182:449-54.
  16. Petrova MM, Shnayder NA, Eryomina OV. Kharakteristika kognitivnykh narusheniy u bol’nykh arterial’noy gipertoniey [Features of cognitive impairments in hypertensive patients]. Kardiovaskulyarnaya terapiya i profilaktika. 2008;7(2):36-9.
  17. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JAMA. 2003;289(19):2560-72.
  18. Skoog I. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on cognition and prognosis in the elderly (SCOPE). Am J Hypertens. 2005;18:1052-9.
  19. Pogosova NV, Boytsov SA, Oganov RG, Kostyuk GP, Sokolova OYu, Yufereva YuM, i dr. Psikhosotsial’nye faktory riska u ambulatornykh patsientov s arterial’noy gipertoniey i ishemicheskoy bolezen’yu serdtsa v 30 gorodakh Rossii: po dannym issledovaniya KOMETA [Psychosocial risk factors of ambulatory patients with arterial hypertension and coronary artery disease in 30 Russians cities: according KOMETA trial]. Kardiologiya. 2018;11:5-16.
  20. Ostroumova OD, Starodubova AV, Ostroumova TM, Chernyaeva MS. Kognitivnye narusheniya i dementsiya u bol’nykh pozhilogo vozrasta s arterial’noy gipertoniey [Cognitive impairments and dementia in elderly hypertensive patients]. Kardiologiya. 2018;10:71-9.
  21. Levi Marpillat N, Macquin-Maver I, Tropeano AL. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens. 2013;31:1073-82.
  22. Chang-Guan H, Hui W, Chao-Min W, Zheng-Rong W, Jun-Wen G. The association of antihypertensive medication use with rick of cognitive decline and dementia: a meta-analysis of longitudinal studies. Int J Clin Pract. 2011;65:1295-305.
  23. Gontarenko SV, Morozova TE. Vliyanie ingibitorov angiotenzinprevrashchaushchego fermenta s razlichnymi farmokologicheskimi svoystvami na kognitivnye funktsii u bol’nykh arterial’noy gipertoniey [Impact of different ACE inhibitors on cognitive functions of hypertensive patients]. Vrach-aspirant. 2014;4:5-11.
  24. Orlova NV, Chukaeva II, Karseladze ND, Alyautdinova IA. Vliyanie perindoprila na parametry mikrotsirkulyattsii i kognitivnye funktsii u patsientov s arterial’noy gipertenziey 1-2 stepeni [Impact of perindopril on microcirculation and cognitive functions of patients with 1-2 stage arterial hypertension]. Lechebnoe delo. 2015;2:38-45.
  25. Morozova TE, Gontorenko SV. Vliyanie antigipertenzivnych preparatov na sostoyanie kognitivnych funktsiy u bol’nykh arterial’noy gipertenziey 1-2 stepeni [Impact of antihypertensive drugs on cognitive functions of patients with 1-2 stage arterial hypertension]. Lechashchiy vrach. 2014;7:15-20.
  26. Fournier A, Oprisiu-Fournier R, Serot JM. Prevention of dementia by antihypertensive drugs: how ATI-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE inhibitors. Expert Rev Neurother. 2009;9:1907-14.
  27. Ostroumova OB, Bobrova TA, Desnitskaya IV. Arterial’naya gipertoniya: vozmozhnosti antigipertenzivnoy terapii [Arterial hypertension: features of antihypertensive therapy]. Serdtse. Zhurnal dlya prakticheskikh vrachey. 2005;6:328-32.
  28. Hanon OP, Berrou JP, Negre-Pages L. Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the observational study on cognitive function and systolic blood pressure reduction open-label study. J Hypertens. 2008;26:1642-50.
  29. Bogatyryova LM. Korrektsiya kognitivnykh narusheniy pri arterial’noy gipertonii [Correction of cognitive impairments for arterial hypertension]. Kardiovaskulyarnaya terapiya i profilaktika. 2016;6:24-7.
  30. Anderson C, Teo K, Gao P. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol. 2011;10:43-53.
  31. Orlova YaA, Plisyuk AG. Novye vozmozhnosti kombinirovannoy terapii arterial’noy gipertonii [New features of combined treatment of arterial hypertension]. Kardiologiya. 2017;6:59-63.
  32. Khoreeva ET, Demyanenko AV, Voronina TC. Vliyanie melatonina na pokazateli tserebral’noy gemodinamiki u bol’nykh gipertonicheskoy bolezn’yu [Impact of melatonin to cerebral hemodynamics in hypertensive patients]. Klinicheskaya meditsina. 2016;1:28-30.
  33. Rapoport SI, Malinovskaya NK. Melatonin i serdechno-sosudistaya sistema. Terapevticheskie vozmozhnosti melatonina u bol’nykh arterial’noy gipertoniey [Melatonin and cardiovascular system. Therapeutic features of melatonin in patients with arterial hypertension]. Russkiy meditsinskiy zhurnal. 2016;3:140-6.
  34. Budnevskiy AV, Ovsyannikov ES, Rezova NV. Melatonin i arterial’naya gipertoniya: vozmozhnaya rol’ v kompleksnoy terapii [Melatonin and arterial hypertension: possible role in complex therapy]. Terapevticheskiy arkhiv. 2017;12:122-6.
  35. Khamidov NKh, Khursanov NM, Saidmurodova FL. Melatonin v lechenii zabolevaniy serdechno-sosudistoy systemy [Melatonin in treatment of cardiovascular pathology]. Izvestiya Akademii nauk Respubliki Tadzhikistan. 2014;1:94-6.
  36. Arushanyan EB, Beyer EV. Gormon mozgovoy zhelezy epifiza melatonin i deyatel’nost’ serdechno-sosudistoy sistemy [Pineal body hormone melatonin and cardiovascular system function]. Meditsiuskiy vestnik Severnogo Kavkaza. 2011;2:90-5.
  37. Arushanyan EB. Universal’nye terapevticheskie vozmozhnosti melatonina [Multipurpose therapeutic features of melatonin]. Klinicheskaya meditsina. 2013;2:4-8.
  38. Vasendin DV. Mediko-biologicheskie effekty melatonina: nekotorye itogi i perspektivy izucheniya [Medical and biological effects of melatonin: some results and perspectives of research]. Vestnik Rossiyskoy voennomeditsinskoy akademii. 2016;3:171-8.
  39. Jean-Louis G, von Gizicki H, Zizi F. Melatonin effect on sleep, mood and cognition in elderly with mild cognitive impairment. J Pineal Res. 1998; 25(3):177-83.
  40. Peck JS, Le Goff DB, Ahmed I, Goebert D. Cognitive effects of exogenous melatonin administration in elderly persons: a pilot study. Am J Geriatr Psych. 2004;12:432-6.
  41. Cardinali DP, Vigo DE, Olivar N. Therapeutic application of melatonin in mild cognitive impairment. Am J Neurodegener Dis. 2012;1:280-91.
  42. Rienmersma-van der Lek RF, Swaab DF, Twisk J. Effect of bright light and melatonin on cognitive and non-cognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA. 2008;299(22):2642-55.
  43. Garzon C, Guerrero JM, Aramburu O, Guzman T. Effect of melatonin administration on sleep, behavioral disorder and hypnotic drug discontinuation in elderly: a randomized double-blind placebo-controlled study. Aging Clin Exp Res. 2009;21(1):38-42.
  44. Zakharov VV, Yakhno NN, Reykhart DV, Zakharova EK, Arnautov VS, Zharkovskiy AM. Kombinatsiya memantina i melatonina pri umerennych kognitivnykh narusheniyakh v pozhilom vozraste: vozmozhnye klinicheskie perpektivy [Combination of memantin and melatonin for mild cognitive impairment in elderly age: possible clinical perspectives]. Nevrologicheskiy zhurnal. 2013;6:40-8.

Authors' information:

Khamidov Nabidzhon Khamidovich
, Corresponding Member of Academy of Sciences of the Republic of Tajikistan, Doctor of Medical Sciences, Full Professor, Professor of the Department of Internal Medicine № 2, Avicenna Tajik State Medical University

Khursanov Nazhmidin Mamatovich
, Candidate of Medical Sciences, Head of the Department of Internal Medicine № 2, Avicenna Tajik State Medical University

Lolaev Anvar Nuralievich
, Applicant of the Department of Internal Medicine № 2, Avicenna Tajik State Medical University

Conflicts of interest: No conflict

Address for correspondence:

Khursanov Nazhmidin Mamatovich
Candidate of Medical Sciences, Head of the Department of Internal Medicine № 2, Avicenna Tajik State Medical University

734003, Republic of Tajikistan, Dushanbe, Rudaki Ave., 139

Tel.: +992 (919) 006207

E-mail: khursanov54@mail.ru

◄ Back to the list